Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch

• Main Authors: José-Manuel Carrascosa (Author), Alessandra Narcisi (Author), Toshifumi Nomura (Author), Sonja Ständer (Author), Christian Vestergaard (Author), Silvia Sabatino (Author), Susanne Grond (Author), Uffe Koppelhus (Author), Mohamed Elrayes (Author), Yun-Fei Chen (Author), Chunyuan Liu (Author), Andreas Wollenberg (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Patients with moderate-to-severe atopic dermatitis (AD) who are most likely to respond to the Janus kinase (JAK) 1/2 inhibitor baricitinib (BARI) are known to have an impacted body surface area (BSA) ≤ 40% and severe itch (numerical rating scale [NRS] ≥ 7], collectively termed...